Application of Quality by Design (QbD) as Artificial Intelligence in Formulation for Diabetes: A Practical Review

The increasing incidence of diabetes has made it essential to create more efficient, customized, and reproducible drug delivery systems. Quality by Design (QbD) is viewed as a science-driven, disciplined approach to drug development that relies more on ensuring consistent product quality through the determination of the Critical Quality Attributes (CQA), Critical Process Parameters (CPP), and development of a Design Space. Nonetheless, the sophistication of contemporary drugs and volumes of data involved tend to confine the independent effectiveness of QbD. Drug development has been transformed by Quality by Design (QbD), which has replaced reactive quality testing with proactive, scientifically based approaches. With its roots in ICH Q8-Q11 principles, QbD places a strong emphasis on defining Critical Quality Attributes (CQAs), creating Design Space, and incorporating risk management to improve the regulatory flexibility and resilience of products.

The review gives a regulatory perspective on QbD and covers important tools from AI such as artificial neural networks (ANN), support vector machines (SVM), and response surface methodology (RSM). In particular, these AI tools offer predictive modeling, pattern recognition, and optimization in support of formulation design. A comprehensive search of PubMed, Google Scholar, and ScienceDirect identified relevant articles focused on the use of AI and machine learning (ML) in diabetes care. Case studies are provided to demonstrate applications in practice, including oral insulin nanoparticles, extended-release metformin, and oral peptide formulations.

By integrating AI with QbD, an ideal environment is created, one that will enhance formulation accuracy, reduce development times, and increase the possibility of regulatory acceptance.

This review investigates the convergence of Artificial Intelligence (AI) technologies and QbD principles in advanced diabetes therapy formulation development. It evaluates how AI tools improve the efficiency, precision, and regulatory acceptability of QbD-guided pharmaceutical design, especially for diabetes therapy.

Although challenges exist with data integrity, regulatory interpretation, and the necessity for a combination of scientific themes, the AI-QbD framework is a transformational journey toward intelligent, patient-focused drug design. Future directions include advances like real-time release testing (RTRT), AI-enabled personalized medicine, and the integration with digital health.